LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Akciju saraksts・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

44.21 -2.41

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

44.05

Max

45.46

Galvenie mērījumi
By Trading Economics
Ienākumi	36M -2.3M
Pārdošana	-3.9M 208M
P/E Sektora vidējais	48.435 49.052
EPS	0.21
Peļņas marža	-1.104
Darbinieki	778
EBITDA	-72M 19M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+37.76% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 4. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-219M 2.6B
Iepriekšējā atvēršanas cena	46.62
Iepriekšējā slēgšanas cena	44.21

Ziņu noskaņojums

By Acuity

50%

161 / 344 Rangs Healthcare

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 11. jūn. 23:56 UTC

News

Monster Beverage shares higher in after-market trading following Bernstein's initiation of coverage with a Market Perform rating. The stock has gained over four consecutive sessions.

2026. g. 11. jūn. 23:52 UTC

Macro Event

News

Correlated Moves

The Australian Dollar has gained against the Singapore Dollar, supported by a slight decline in consumer inflation expectations and recent geopolitical developments.

2026. g. 11. jūn. 23:51 UTC

News

The iShares Core U.S. Aggregate Bond ETF is trading lower in after-market hours, reflecting concerns over inflation following a rise in the producer price index.

2026. g. 11. jūn. 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

SPDR S&P 500 ETF Trust rises in after-hours trading amid improved market sentiment and reduced geopolitical tensions in Iran, supported by strong performances from top holdings.

2026. g. 11. jūn. 23:51 UTC

Correlated Moves

ETF Constituents

News

Social Media

Invesco QQQ Trust Series I rises after hours, supported by a Nasdaq 100 rally driven by technology stocks and easing inflation concerns.

2026. g. 11. jūn. 23:51 UTC

News

The United States Oil Fund LP is higher in after-market trading amid reports of explosions in Iran raising concerns over oil supply stability.

2026. g. 11. jūn. 23:41 UTC

Social Media

News

Event

Adobe Inc. shares fell in after-market trading despite record revenue of $6.62 billion, as investor concerns grew over CFO Dan Durn's upcoming departure.

2026. g. 11. jūn. 23:41 UTC

ETF Constituents

Correlated Moves

Macro News

News

Vanguard Information Technology ETF rises after President Trump's decision to call off attacks against Iran, boosting investor confidence and contributing to gains in major indices.

2026. g. 11. jūn. 23:41 UTC

Social Media

News

Western Digital Corp initiated exchange agreements with investors for over 1 million shares of SanDisk, contributing to the stock's higher after-market hours movement.

2026. g. 11. jūn. 23:36 UTC

News

Correlated Moves

Ethereum is trading higher as market optimism rises amid U.S.-Iran tensions and the European Central Bank's interest rate hike. Earlier, it pulled back from a peak.

2026. g. 11. jūn. 23:31 UTC

News

NVIDIA shares are higher in after-market trading following an upgrade to 'AA' by S&P Global and the announcement of its 2026 Annual Meeting.

2026. g. 11. jūn. 23:26 UTC

ETF Constituents

Correlated Moves

News

Vanguard Growth ETF rises in after-market trading, buoyed by gains from Microsoft, NVIDIA, and Alphabet, despite remaining below its 20-day moving average.

2026. g. 11. jūn. 23:16 UTC

ETF Constituents

Social Media

News

Correlated Moves

The iShares Russell 2000 ETF rose in after-market hours, supported by the Russell 2000 index's significant gain and contributions from PR and SATS.

2026. g. 11. jūn. 23:11 UTC

News

Correlated Moves

CME Group plans to expand 24/7 gold trading, pending regulatory review. SPDR Gold Shares are rising in after-market hours amid geopolitical tensions.

2026. g. 11. jūn. 23:11 UTC

News

USD/PLN trades lower as natural gas storage exceeds forecasts and initial jobless claims rise unexpectedly. Volatility persists during Thursday's session.

2026. g. 11. jūn. 23:11 UTC

News

Correlated Moves

The USD/CZK is trading lower, reflecting a decline since Wednesday's close amid rising initial jobless claims and producer prices exceeding forecasts.

2026. g. 11. jūn. 23:06 UTC

Correlated Moves

News

Vanguard Total Bond Market ETF trades higher in after-market hours as producer prices exceed expectations, prompting bargain hunting despite potential interest rate hike concerns.

2026. g. 11. jūn. 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

2026. g. 11. jūn. 23:03 UTC

Social Media

Correlated Moves

News

iShares Silver Trust trades higher after geopolitical tensions in Iran raise interest in safe-haven assets, supported by gold's recent gains.

2026. g. 11. jūn. 23:03 UTC

ETF Constituents

News

The Vanguard Small-Cap ETF is higher in after-market trading, reflecting a broader upward trend in the Russell 2000 Index amid ongoing inflationary concerns.

2026. g. 11. jūn. 23:02 UTC

News

The USD/THB is lower as U.S. economic data raises inflation concerns, impacting sentiment and Federal Reserve policy expectations during Thursday's trading session.

2026. g. 11. jūn. 23:02 UTC

News

Gilead Sciences reported positive results from two Phase 3 trials for an HIV treatment. Shares are higher in after-market hours following a session pullback.

2026. g. 11. jūn. 23:02 UTC

News

The USD/HUF is trading lower, reflecting a drop since Wednesday. Rising jobless claims and surging producer prices raise concerns about labor market strength and inflation.

2026. g. 11. jūn. 23:02 UTC

Correlated Moves

News

The USD/SEK is declining, breaking a trend of higher daily closes, amid rising initial jobless claims that may impact Federal Reserve policy.

2026. g. 11. jūn. 22:51 UTC

Correlated Moves

News

USD/SGD declines amid natural gas storage data surpassing forecasts. The pair has experienced unusual volatility, peaking briefly before steady declines into the afternoon.

2026. g. 11. jūn. 22:51 UTC

Correlated Moves

News

The CHF/HKD is higher during Thursday's session, supported by the European Central Bank's recent interest rate hike amid inflation pressures.

2026. g. 11. jūn. 20:07 UTC

News

Correlated Moves

The European Central Bank raised interest rates by 25 basis points, supporting modest gains in GBP/HKD amid inflation pressures from the Middle East conflict.

2026. g. 11. jūn. 20:07 UTC

News

Correlated Moves

Natural gas storage data showed 108 billion cubic feet, surpassing forecasts. USD/NOK is trading higher, remaining above its 20-day moving average.

2026. g. 11. jūn. 20:07 UTC

News

Correlated Moves

The USD/DKK is lower in Thursday's session, reflecting a decline in the US Dollar Index amid rising initial jobless claims data.

2026. g. 11. jūn. 20:06 UTC

News

Correlated Moves

Intel Corp's stock is rising following a double upgrade from Bank of America, which raised its price target to $135 from $96.

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

37.76% augšup

Prognoze 12 mēnešiem

Vidējais 62.75 USD 37.76%

Augstākais 66 USD

Zemākais 55 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

161 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.